News | June 22, 2026
Sun Pharma to acquire Innovcare Lifesciences for Rs. 271.2 crore
Acquisition of Mumbai-based pharmaceutical, nutraceutical and cosmeceutical company expected to be completed by July 2026
Acquisition of Mumbai-based pharmaceutical, nutraceutical and cosmeceutical company expected to be completed by July 2026
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
This includes 14.3 million views on YouTube and 9.8 million views on Meta platforms to amplify preventive heart health message
Company to launch product after the expiry of semaglutide patent in India
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
